Form 4: BioCardia CEO Peter Altman Increases Stake in Company
SEC Form 4 Filing
BioCardia's President and CEO, Peter Altman, recently purchased 1,200 shares of the company's common stock at an average price of $2.24 per share.
Summary
- On April 3, 2025, Peter Altman, the President and CEO of BioCardia, Inc., acquired 1,200 shares of common stock.
- The purchase was made at a weighted average price of $2.24 per share.
- Following the transaction, Altman directly owns 109,620 shares of BioCardia's common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO buying shares is generally a good sign, but the purchase is relatively small and doesn't provide a strong signal.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/03/2025 | Date of the transaction where Peter Altman purchased 1,200 shares of BioCardia's common stock. |
Keywords
BioCardia, BCDA, Peter Altman, insider trading, stock purchase, Form 4, ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.